Patents by Inventor Gisèle LaPointe

Gisèle LaPointe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lantibiotic from Streptococcus mutans, method of production and use thereof
    Patent number: 6699839
    Abstract: Mutacin are bactericidal substances of proteinaceous natures produced by Streptococcus mutans. Lantibiotics are antibacterial substances containing posttranslationnally modified amino acids such as lanthionine. The present invention teaches a simple method of purifying mutacin B-Ny266 from Streptococcus mutans strain Ny266 to homogeneity. The present invention further teaches the primary amino acid sequence of mutacin B-Ny266 as well as its proposed modified structure. Further, the present invention teaches compositions comprising mutacin B-Ny266 as well as methods for the treatment and/or prophylaxy of bacterial infections comprising an administration of a suitable dose of composition comprising mutacin B-Ny266.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: March 2, 2004
    Assignee: Universite Laval
    Inventors: Marc Lavoie, Marilaine Mota-Meira, Christophe Lacroix, Gisèle Lapointe
  • Lantibiotic from Streptococcus mutans and uses thereof
    Patent number: 6218362
    Abstract: Mutacin are bactericidal substances of proteinaceous natures produced by Streptococcus mutans. Lantibiotics are antibacterial substances containing posttranslationnally modified amino acids such as lanthionine. The present invention teaches a simple method of purifying mutacin B-Ny266 from Streptococcus mutans strain Ny266 to homogeneity. The present invention further teaches the primary amino acid sequence of mutacin B-Ny266 as well as its proposed modified structure. Further, the present invention teaches compositions comprising mutacin B-Ny266 as well as methods for the treatment and/or prophylaxy of bacterial infections comprising an administration of a suitable dose of composition comprising mutacin B-Ny266.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: April 17, 2001
    Assignee: Universite Laval
    Inventors: Marc Lavoie, Marilaine Mota-Meira, Christophe Lacroix, Gisèle LaPointe